Sunil Healthcare (537253)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trades near book value: P/B 1.13 against ₹70.97 book value, offering some downside cushion if assets are genuine.
• Piotroski F-Score of 7/9 suggests improving financial health, not a deteriorating balance sheet.
• Profit growth of 209.26% and PEG of 0.22 show strong earnings momentum, though from a low base.
• Sales growth of 6.74% and latest quarter revenue of ₹22 Cr provide modest operating stability.

Concerns

• ROE of 2.40% and ROCE of 3.96% are far below acceptable returns on capital; business quality is weak.
• P/E of 23.66 is rich for a company with such low returns and thin net margins.
• Zero dividend yield means no income return; investor relies entirely on uncertain capital appreciation.
• Debt/Equity and promoter holding are not disclosed, reducing transparency for a small retail investor.

AI Analysis

Let me begin with the obvious: this small pharma company earns far too little on the capital employed. With a book value of ₹70.97 and a price of ₹80, I am paying a small premium to net worth. But a P/B ratio only matters if the business generates attractive returns on that book. Sunil Healthcare's ROE is 2.40% and ROCE is 3.96%. That is below what a risk-free fixed deposit would earn, and no shareholder is being paid to wait—the dividend yield is zero. This is not a wonderful business; it is a capital-intensive commodity exposed to pricing and regulatory pressures without an evident moat. The profit growth figure of 209.26% catches the eye, but Graham taught me to distrust percentages from a tiny base. Trailing earnings put the P/E at 23.66, and the latest quarter's ₹1 Cr profit on ₹22 Cr sales suggests a net margin of only around 4.5%. That is thin. The PEG ratio of 0.22 is meaningless if the 209% growth is a one-time bounce. Still, I must credit what is good. The Piotroski F-Score of 7/9 signals improving financials, and the stock trades close to book value, so downside may be cushioned if the balance sheet is solid. Sales growth of 6.74% is modest but positive. Would I buy this? As a margin-of-safety investor, I need both a good business and a low price. Here the price is lowish, but the business quality is weak. I would want years of higher ROE, no hidden debt, and clear evidence of pricing power before calling this a value investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer